Kodiak Sciences announces the initiation of regulatory submissions for its Phase 3 successful ophthalmology drug candidates by October 12, 2026.
Posted 2026-09-28 — 14 days before the deadline, stated before the outcome.
The claim
Kodiak Sciences announces the initiation of regulatory submissions for its Phase 3 successful ophthalmology drug candidates by October 12, 2026.
Reasoning trace
- Immediate positive Phase 3 data for multiple candidates threatening Regeneron's Eylea
- Significant market value increase ($3B) indicating investor confidence in commercial readiness
- Standard biotech practice to initiate regulatory filings promptly after pivotal success to secure approval timelines
Evidence so far
2 confirming · 0 denying signals · 0 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 2 times since mint (last on 2026-09-29) — 87% at mint → 78% today.
What to watch
- leading indicator Kodiak Sciences files a Form 8-K with the SEC explicitly stating the initiation of regulatory submissions for a Phase 3 ophthalmology drug candidate
- milestone Kodiak Sciences submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for a Phase 3 ophthalmology candidate
- leading indicator Kodiak Sciences issues a press release announcing the filing of a BLA or NDA for an ophthalmology drug candidate.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.